Legend Biotech Corp. reported a robust performance for Q4 2024, driven by a significant increase in CARVICTI sales. The company achieved net sales of $334 million for CARVICTI, marking a 110% ...
Legend Biotech Corp (LEGN) reported its second-quarter earnings for 2025, revealing a significant increase in revenue but a larger-than-expected loss per share. The company’s revenue reached 255.06 ...
Legend Biotech Corp (LEGN) reported robust financial results for Q1 2025, driven by significant sales growth of its flagship product, CARVICTI. The company posted total revenues of $195 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results